Omnicell (NASDAQ:OMCL) Issues Earnings Results, Misses Estimates By $0.12 EPS

Omnicell (NASDAQ:OMCL) issued its earnings results on Thursday. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12), Zacks reports. Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. Omnicell updated its Q1 2025 guidance to 0.150-0.250 EPS and its FY 2025 guidance to 1.650-1.850 EPS.

Omnicell Stock Down 11.2 %

Shares of NASDAQ OMCL opened at $39.43 on Friday. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74. The stock has a fifty day moving average price of $44.52 and a two-hundred day moving average price of $43.23.

Insider Activity

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now directly owns 58,427 shares in the company, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on OMCL. Craig Hallum increased their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company dropped their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Benchmark reiterated a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research report on Tuesday. Bank of America lowered their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Finally, StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $52.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.